Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of HZ-H08905 in relapsed and/or refractory peripheral T-cell lymphoma
CTR20240745Phase 2Active
- Sponsor
- Hezheng Pharma
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HZ-H08905 in peripheral T-cell lymphoma (PTCL), sponsored by Hezheng Pharma. Started Mar 2024; status: active.
02
Drugs
HZ-H08905
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on CTR20240745.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240745.